WEATHER ALERT

Deadline fast approaching for Canadians to file claim in class-action drug suit

Advertisement

Advertise with us

MONTREAL - The deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.

Read this article for free:

or

Already have an account? Log in here »

We need your support!
Local journalism needs your support!

As we navigate through unprecedented times, our journalists are working harder than ever to bring you the latest local updates to keep you safe and informed.

Now, more than ever, we need your support.

Starting at $15.99 plus taxes every four weeks you can access your Brandon Sun online and full access to all content as it appears on our website.

Subscribe Now

or call circulation directly at (204) 727-0527.

Your pledge helps to ensure we provide the news that matters most to your community!

To continue reading, please subscribe:

Add Brandon Sun access to your Free Press subscription for only an additional

$1 for the first 4 weeks*

  • Enjoy unlimited reading on brandonsun.com
  • Read the Brandon Sun E-Edition, our digital replica newspaper
Start now

*Your next Free Press subscription payment will increase by $1.00 and you will be charged $20.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.

MONTREAL – The deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.

Canadians have until Aug. 27 to file a claim for their share of a $4.75 million settlement over the antipsychotic medication used to treat schizophrenia and depression.

Quebec Superior Court approved the settlement in November, one year after authorizing the national class action against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.

The Palais de Justice, Quebec Superior Court, is seen in Montreal, on Monday, Aug. 18, 2025. THE CANADIAN PRESS/Christinne Muschi
The Palais de Justice, Quebec Superior Court, is seen in Montreal, on Monday, Aug. 18, 2025. THE CANADIAN PRESS/Christinne Muschi

The class action covers Canadians who were prescribed the drug since February 2017 and later developed compulsive behaviours or impulse-control disorders such as gambling, shopping or binge-eating.

Lawyers representing affected patients and families have said the deal is a compromise with no admission of liability. 

Applicants could receive anywhere from roughly $6,500 for mild cases to more than $102,000 in more severe cases.

This report by The Canadian Press was first published July 27, 2026.

Report Error Submit a Tip

National

LOAD NATIONAL ARTICLES